Equities

Vivani Medical Inc

Vivani Medical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.13
  • Today's Change-0.02 / -1.74%
  • Shares traded103.00
  • 1 Year change+9.71%
  • Beta3.2254
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.

  • Revenue in USD (TTM)0.00
  • Net income in USD-24.20m
  • Incorporated2003
  • Employees44.00
  • Location
    Vivani Medical Inc1350 S. LOOP ROADALAMEDA 94502United StatesUSA
  • Phone+1 (818) 833-5000
  • Fax+1 (818) 833-5067
  • Websitehttp://www.secondsight.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Omega Therapeutics Inc6.31m-78.90m59.02m93.00--2.25--9.35-1.43-1.430.11450.47620.0318--6.6767,892.48-39.72---46.68-------1,249.54------0.3917--49.25--5.13------
Mural Oncology PLC0.00-173.30m59.12m117.00--0.2871-----10.35-10.350.0012.090.00----0.00-131.01---164.28--------------0.00-------9.29------
Aerovate Therapeutics Inc0.00-87.94m59.18m51.00--0.6266-----3.14-3.140.003.270.00----0.00-65.76---74.16--------------0.00-------46.61------
Shattuck Labs Inc4.12m-85.28m60.14m75.00--0.5437--14.58-1.85-1.850.08832.320.029----54,986.67-60.08-29.14-66.66-32.42-----2,067.99-565.33----0.00--154.14-40.6214.37---19.15--
Bioqual Inc62.86m957.02k60.37m108.0063.081.5517.210.96041.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Renovaro Inc0.00-88.12m60.85m11.00--0.3609-----1.08-1.080.001.140.00----0.00-60.56-27.81-68.21-28.44-----------24.380.0405------65.02---0.1538--
Regencell Bioscience Holdings Ltd0.00-4.71m61.16m12.00--6.02-----0.362-0.3620.000.7810.00----0.00-37.91---37.91--------------0.00------21.15------
Serina Therapeutics Inc179.00k-18.67m61.99m4.00------346.33-9.72-9.720.0403-1.860.0156--6.2844,750.00-162.58-194.46----49.7285.80-10,438.55-2,347.36---1.82----317.65-36.69-41.49------
Champions Oncology Inc51.66m-3.40m62.40m210.00------1.21-0.2541-0.25413.78-0.02441.88--5.75245,976.20-12.39-10.00-44.43-23.0044.2746.58-6.58-6.04----333.00---6.9013.13-36.38--0.0479--
Vivani Medical Inc0.00-24.20m62.44m44.00--2.62-----0.4643-0.46430.000.43160.00----0.00-44.89-56.58-50.97-67.66-------2,868.72----0.00-------84.69--40.33--
RetinalGenix Technologies Inc0.00-4.04m62.99m0.00---------0.2291-0.22910.00-0.1010.00-------9,059.05-9,163.75---------------1,050.46--------46.58------
OS Therapies Inc0.00-6.55m63.16m4.00---------0.3011-0.30110.00-1.32------0.00-------------------0.9763---------24.09------
Maia Biotechnology Inc0.00-28.08m63.59m13.00--19.97-----1.62-1.620.000.13320.00----0.00-251.96---362.21--------------0.00-------21.91------
Rapt Therapeutics Inc0.00-120.43m65.62m122.00--0.6008-----3.12-3.120.003.130.00----0.00-69.23-46.30-75.81-49.97-------3,522.72----0.00---100.00---39.31---20.31--
Precision BioSciences Inc87.64m15.79m66.19m110.00--0.87243.160.7552-0.13630.20217.5910.490.5044--79.03804,036.709.09-35.3512.24-44.22----18.02-147.50----0.2314--94.1534.9641.67---32.01--
Data as of Oct 08 2024. Currency figures normalised to Vivani Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

10.97%Per cent of shares held by top holders
HolderShares% Held
Sabby Management LLCas of 31 Mar 20242.67m4.86%
Tanager Wealth Management LLPas of 30 Jun 20241.30m2.37%
The Vanguard Group, Inc.as of 31 Mar 2024833.84k1.52%
Commonwealth Equity Services LLCas of 30 Jun 2024330.53k0.60%
Geode Capital Management LLCas of 30 Jun 2024327.88k0.60%
Monetary Management Group, Inc.as of 30 Jun 2024193.98k0.35%
SSgA Funds Management, Inc.as of 31 Mar 2024159.40k0.29%
Evoke Wealth LLCas of 31 Mar 202499.87k0.18%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202460.42k0.11%
BlackRock Fund Advisorsas of 31 Mar 202450.30k0.09%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.